Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
PH-284 by VistaGen Therapeutics for Cachexia: Likelihood of Approval
PH-284 is under clinical development by VistaGen Therapeutics and currently in Phase II for Cachexia. According to GlobalData, Phase II...